Franklin Resources Inc. Cuts Stock Holdings in Dyne Therapeutics, Inc. $DYN

Franklin Resources Inc. lessened its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 1.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,390,140 shares of the company's stock after selling 24,695 shares during the quarter. Franklin Resources Inc. owned 0.98% of Dyne Therapeutics worth $13,234,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Y Intercept Hong Kong Ltd boosted its stake in shares of Dyne Therapeutics by 54.5% in the second quarter. Y Intercept Hong Kong Ltd now owns 124,628 shares of the company's stock valued at $1,186,000 after buying an additional 43,963 shares in the last quarter. Graham Capital Management L.P. purchased a new position in Dyne Therapeutics in the first quarter worth $651,000. Arcadia Investment Management Corp MI lifted its holdings in Dyne Therapeutics by 23.1% in the second quarter. Arcadia Investment Management Corp MI now owns 55,215 shares of the company's stock valued at $526,000 after acquiring an additional 10,350 shares during the period. Bryce Point Capital LLC acquired a new stake in Dyne Therapeutics in the second quarter valued at $115,000. Finally, Voleon Capital Management LP purchased a new stake in shares of Dyne Therapeutics during the 1st quarter worth $624,000. Institutional investors and hedge funds own 96.68% of the company's stock.

Dyne Therapeutics Stock Performance

NASDAQ:DYN opened at $21.92 on Friday. The company has a current ratio of 16.83, a quick ratio of 16.83 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $3.13 billion, a P/E ratio of -5.68 and a beta of 1.16. The firm has a 50-day moving average price of $17.73 and a two-hundred day moving average price of $13.70. Dyne Therapeutics, Inc. has a twelve month low of $6.36 and a twelve month high of $31.29.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.05. As a group, research analysts expect that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Dyne Therapeutics news, CEO John Cox sold 2,640 shares of the stock in a transaction on Friday, September 5th. The stock was sold at an average price of $13.41, for a total transaction of $35,402.40. Following the sale, the chief executive officer owned 199,539 shares in the company, valued at approximately $2,675,817.99. This represents a 1.31% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 20.77% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Lifesci Capital upgraded shares of Dyne Therapeutics to a "strong-buy" rating in a report on Tuesday, October 14th. Weiss Ratings restated a "sell (d-)" rating on shares of Dyne Therapeutics in a research report on Wednesday, October 8th. Evercore ISI reaffirmed an "outperform" rating and issued a $38.00 target price on shares of Dyne Therapeutics in a report on Thursday, November 6th. Raymond James Financial raised Dyne Therapeutics from an "outperform" rating to a "strong-buy" rating and boosted their price target for the stock from $31.00 to $35.00 in a research note on Monday, August 25th. Finally, Sanford C. Bernstein restated a "market perform" rating and issued a $21.00 price target on shares of Dyne Therapeutics in a report on Tuesday. Four investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $35.47.

Check Out Our Latest Stock Analysis on Dyne Therapeutics

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

Read More

• Five stocks we like better than Dyne Therapeutics
• Find and Profitably Trade Stocks at 52-Week Lows
• Power On: Applied Digital’s First AI Data Center Goes Live
• Low PE Growth Stocks: Unlocking Investment Opportunities
• Alphabet: The AI Leader Best Positioned to Dominate 2026
• 3 Defense Stocks Set to Benefit From Increased Military Spending
• 2 Reasons to Load Up on Fiserv, 1 to Stay Away

Want to see what other hedge funds are holding DYN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Dyne Therapeutics Right Now?

Before you consider Dyne Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dyne Therapeutics wasn't on the list.

While Dyne Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here